- Academic Editor
†These authors contributed equally.
Background: The causes of atrioventricular block (AVB) are different and diverse young patients, as compared to the old. However, little is known about the etiology distribution and clinical characteristics of AVB in the young group. Methods: We retrospectively analyzed clinical information for AVB patients under 50 years of age. We summarized clinical phenotypes for patients with undetermined AVB etiology, according to AVB type and cardiac-structural change, whereas those who received pacing therapy were followed up for suspected heart failure events (HFEs). Results: AVB etiology was identified in only 289 (61.4%) patients, while 38.6% still have undertermined etiology for AVB. Non-ischemic cardiomyopathy (16.6%) and complication of cardiac surgery (13.4%) were the top two etiologies. In addition, four distinct phenotypes were identified in AVB patients with undetermined etiology, of which the severe phenotype (both borderline/elevated left ventricular diameter or abnormal left ventricular ejection fraction and advanced AVB) accounted for 17%. Notably, 80.7% of patients with severe phenotype received pacing therapy. Based on a median follow-up time of 17.5 months, we found the occurrence of 16 suspected HFEs in 110 pacemaker receivers (12 were lost to follow up). Notably, the severe phenotype was associated with a higher risk of heart failure (HF) symptoms. Conclusions: AVB etiology in young patients under 50 years of age is complex and underdiagnosed. In patients with undetermined etiology, severe phenotype featuring advanced AVB and abnormal Left ventricle (LV) structure/function is associated with a higher rate of HF symptoms even after pacing therapy.
Atrioventricular block (AVB) is a common and significant cardiac conduction disorder, with a high rate of pacemaker implantation [1, 2]. Previous studies have reported higher morbidity and mortality rates in elderly AVB patients, mainly due to the occurrence of idiopathic aging-related fibrosis of the cardiac conduction system [3, 4]. For decades, pacing has been considered the “one size fits all” approach for alleviating AVB symptoms [5]. Early AVB onset cannot be ignored in the young population, although its occurrence is rare; a previous study reported prevalence rates of 2.67‰ and 6.23‰ in Chinese patients aged 18–39 and 40–59 years, respectively [6]. Evidence from western countries has demonstrated that the etiologic spectrum of AVB is more diverse in the young population, and may range from congenital heart disease (CHD) to rare cardiomyopathy [7, 8, 9]. Premature AVB in young patients can affect their productive years due to the probable longer disease courses, as well as the economic burden associated with medical treatment. Nevertheless, pacing does not achieve as excellent a prognosis in the young population as it does in older patients. Findings from a large-scale cohort study revealed that younger patients had a higher relative risk of heart failure (HF) hospitalization than did their older counterparts, which might be attributed to a synergistic effect of the progression of underlying etiologies and long-term high right ventricular pacing (RVP) rate [10, 11]. However, the clinical decision for AVB treatment is mainly made based on the AVB blocking site, with little attention paid to the underlying causes of the condition [1].
Determination of presumed AVB etiology in young patients is also necessary for a deep understanding of the underlying disease mechanism, timely assessment of an individual’s prognosis, and appropriate application of treatment therapies [12]. To date, however, early-onset AVB remains underappreciated with no integrated descriptions of etiology and clinical characteristics, especially in the Chinese population. In the present study, we report etiologic distribution and clinical characteristics of AVB patients younger than 50 years, and evaluate the relationship between etiology, blocking type, and cardiac structural/functional change to provide new insights about AVB in the young group.
This single-center retrospective study included AVB patients aged
Two trained physicians independently performed in-depth reviews of the medical records, based on a pre-defined etiologic classification. Any disagreement between them, with regard to etiologic determination, was adjudicated by a senior consultant. Congenital AVB (CAVB) was considered etiology if AVB was diagnosed in utero, at birth, or within the first month of life, in addition to any evidence of abnormal maternal anti-SSA/Ro-SSB/La antibodies [13]. CHD was considered etiology if AVB occurred in the setting of significant cardiac defects, including AV septal defects, secundum atrial septal defects, ventricle defects, Steno-Fallot tetralogy, transposition of the great arteries, or univentricular heart anatomy [14, 15]. On the other hand, etiology was registered as hereditary if both the familial trend and a proven pathogenic gene mutation were identified. AVB was considered a complication of cardiac surgery (including transcatheter aortic valve replacement) or intracardiac ablation, if there was no evidence of AVB prior to the operation but there was within 30 days after operation [16, 17]. AVB cases with a confirmed diagnosis of non-ischemic cardiomyopathy (NICM), infiltrative cardiomyopathy, neuromuscular disease, a confirmed history of myocarditis, Long QT (LQT), Brugada syndrome (BrS), or immune disease (systemic sclerosis, Sjogren’s syndrome, systemic lupus erythematosus, reactive arthritis, or other auto-immune diseases) were all classified as etiology [3, 18, 19, 20, 21]. Endocrine-related AVB was registered if a patient presented with thyroid dysfunction that was resolved after corrected thyroid function [22]. Ischemic heart disease (IHD) was considered etiology if patients developed AVB due to myocardial infarction or were found to have AVB during angina. Drug-related AVB was considered etiology if AVB occurred during therapy with a calcium channel blocker, digoxin, beta-blockers, or antiarrhythmic drugs, but was resolved and did not recur after discontinuation of the drug [23]. Vagal mediation was diagnosed if AVB was associated with high vagal tone, such as during sleep, accompanied by slowing of sinus rhythm documented during a tilt test [24].
Baseline echocardiography was performed in the same laboratory and reviewed by
an experienced sonographer. The left atrium dimension was measured in the
anterior-posterior plane, at the level of aortic sinuses, whereas the left
ventricular ejection fraction (LVEF) was measured via unenhanced 2D
echocardiography using the modified Simpson biplane method. The diameter of right
ventricle (RV) was measured at the mid-level of the RV. Blood samples were
collected from each patient 1–3 days after admission, and creatinine kinase and
N-terminal B-type natriuretic peptide (NT-proBNP) were directly measured using a
commercial chemiluminescence assay (Roche Diagnostics GmbH, Mannheim, Germany),
according to the manufacturer’s instructions. Borderline or elevated left
ventricle diastolic diameter (LVEDD) was defined if the value exceeded 55 mm for
an adult male patient, or 50 mm for women and pediatric patients [25]. Abnormal
LVEF was defined as a LVEF value of ˂50% for adults or ˂60% for pediatrics. HF
with reduced ejection fraction (HFrEF, LVEF
Patients with undetermined AVB causes and receiving pacing therapy were followed up via outpatient review or telephone by physicians, for suspected HF events (HFEs) defined as new onset of HF-related symptoms and signs, unplanned clinic visit, or hospitalization due to the symptoms. Specifically, we measured the duration from pacemaker implantation to the latest follow-up time, as well as the time to event or loss to follow-up, for each patient. The target HF-related signs and symptoms included breathlessness, fatigue, depression, and decreased exercise tolerance, as well as symptoms of volume overload, such as swelling of the legs or increase in abdominal distension, as previously described [28, 29]. The echocardiographic results during follow-up at either our outpatient clinic or the local hospital were also recorded if avialiable.
Conservatively calculating, a sample size of 503 produces a two-tailed 95%
confidence interval with a width equal to 0.100 when considering an etiology
proportion of 50% and 20% of records with missing data. Continuous variables
were expressed as mean (standard deviation) if they were normally distributed,
otherwise, they were presented as median (interquartile range). Categorical
variables were presented as numbers and proportions. Proportions were compared
using the Chi-Square or Fisher exact probability test, as appropriate.
Comparisons between two groups of continuous variables were performed using a
Students’ t-test, analysis of variance (ANOVA), Mann–Whitney U test, or Kruskal-Wallis test,
as appropriate. We also generated Kaplan-Meier survival curves with a log-rank
test to compare event-free survival rates between patients with severe phenotype
and non-severe phenotype in an unknown etiology group with pacing therapy.
Univariate and multivariate analyses were conducted using Cox proportional hazard
model and binary logistic regression model. Statistical tests were two-tailed,
with p
Among the initial 549 eligible AVB cases aged
Flowchart for inclusion of inpatients with the atrioventricular block below 50 years old. AVB, atrioventricular block.
Total (n = 471) | Known reason (n = 289) | Unknow reason (n = 182) | p-value | |||
Age, yrs | 34.1 |
33.5 |
35.0 |
0.192 | ||
Male sex, n % | 291 (61.8%) | 192 (66.4%) | 99 (54.4%) | 0.009 | ||
BMI, kg/m |
23.7 |
23.6 |
23.7 |
0.805 | ||
Onset age, yrs | 31.0 |
30.4 |
31.85 |
0.273 | ||
Family history, n % | 33 (7.0%) | 21 (7.3%) | 12 (6.6%) | 0.781 | ||
Symptoms | ||||||
Dizziness, n % | 96 (20.4%) | 45 (15.6%) | 51 (28.0%) | 0.001 | ||
Chest tightness, n % | 138 (29.3%) | 90 (31.1%) | 48 (26.4%) | 0.268 | ||
Palpitation, n % | 135 (28.7%) | 77 (26.6%) | 58 (31.8%) | 0.222 | ||
Amaurosis, n % | 77 (16.4%) | 41 (14.2%) | 36 (19.8%) | 0.110 | ||
Fatigue, n % | 82 (17.4%) | 34 (11.7%) | 48 (26.4%) | |||
Syncope, n % | 88 (18.7%) | 48 (16.6%) | 40 (22.0%) | |||
Asymptomatic, n % | 70 (14.9%) | 41 (14.2%) | 29 (15.9%) | 0.604 | ||
Comorbidities | ||||||
Coronary artery disease, n % | 63 (13.4%) | 53 (18.3%) | 10 (5.5%) | |||
Valve disease, n % | 125 (26.5%) | 106 (36.7%) | 19 (10.4%) | |||
Pulmonary artery hypertension, n % | 65 (13.8%) | 52 (18.0%) | 13 (7.1%) | |||
Stroke, n % | 15 (3.2%) | 11 (3.8%) | 4 (2.2%) | 0.333 | ||
Vasovagal syncope, n % | 12 (2.6%) | 9 (3.1%) | 3 (1.7%) | 0.326 | ||
OSAHS, n % | 37 (7.7%) | 26 (9.0%) | 11 (6.0%) | 0.246 | ||
Diabetes, n % | 43 (9.1%) | 31 (10.7%) | 12 (6.6%) | 0.129 | ||
Myocarditis, n % | 18 (3.8%) | 16 (5.5%) | 2 (1.1%) | 0.014 | ||
Thyroid disease, n % | 24 (5.10%) | 17 (5.88%) | 7 (3.85%) | 0.328 | ||
Chronic kidney disease, n % | 15 (3.18%) | 13 (4.50%) | 2 (1.10%) | 0.041 | ||
Hypertension, n % | 81 (17.2%) | 52 (18.0%) | 29 (15.9%) | 0.564 | ||
NYHA class | 1.6 |
1.8 |
1.2 |
|||
I, n % | 309 (65.6%) | 151 (52.3%) | 158 (86.8%) | |||
II, n % | 85 (18.0%) | 69 (23.9%) | 16 (8.8%) | |||
III, n % | 56 (11.9%) | 48 (16.6%) | 8 (4.4%) | |||
IV, n % | 21 (4.5%) | 21 (7.2%) | 0 (0.0%) | |||
AVB type | ||||||
Mild AVB, n % | 152 (32.3%) | 95 (32.9%) | 57 (31.3%) | 0.726 | ||
Advanced AVB, n % | 319 (67.7%) | 194 (67.1%) | 125 (68.7%) | |||
Mobitz type II | 47 (14.7%) | 26 (13.4%) | 21 (16.8%) | |||
High degree AVB | 53 (16.6%) | 28 (14.4%) | 25 (20.0%) | |||
Third degree AVB | 219 (68.7%) | 140 (72.2%) | 79 (63.2%) | |||
ECG features | ||||||
Heart rate, bpm | 59.0 (43.5–72.5) | 62.0 (44.0–74.0) | 56.0 (43.0–70.8) | 0.042 | ||
Atrial fibrillation/flutter, n % | 75 (15.9%) | 50 (17.3%) | 25 (13.7%) | 0.303 | ||
LBBB, n % | 37 (7.9%) | 25 (8.7%) | 12 (6.6%) | 0.419 | ||
RBBB, n % | 73 (15.5%) | 59 (20.4%) | 14 (7.7%) | |||
No sustained VT, n % | 54 (11.5%) | 42 (14.5%) | 12 (6.6%) | 0.008 | ||
Echocardiographic features | ||||||
Left atrial diameter, mm | 36.3 |
37.2 |
34.8 |
0.004 | ||
Left ventricular end diastolic diameter, mm | 49.6 |
49.9 |
49.1 |
0.446 | ||
LVEF, % | 58.3 |
55.6 |
62.7 |
|||
Right ventricular diameter, mm | 24.2 |
24.8 |
23.3 |
0.016 | ||
Abnormal TAPSE, n % | 46 (9.8%) | 42 (14.5%) | 4 (2.2%) | |||
Abnormal LVEF, n % | 81 (17.2%) | 75 (26.0%) | 6 (3.3%) | |||
HFrEF, n % | 53 (11.3%) | 52 (18.0%) | 1 (0.6%) | |||
Borderline/elevated Left ventricle, n % | 129 (27.4%) | 92 (31.8%) | 37 (20.3%) | 0.006 | ||
NT-proBNP, pg/mL | 212.0 (52.8–940.5) | 495.0 (103.00–1702.4) | 70.2 (26.0–312.6) | |||
CK, IU/L | 76.0 (53.0–112.5) | 75.0 (50.0–121.0) | 79.0 (58.00–105.5) | 0.870 | ||
CIED implantation | 258 (54.8%) | 148 (51.2%) | 110 (60.4%) | 0.050 | ||
CRT (D), n % | 11 (2.3%) | 9 (3.1%) | 2 (1.1%) | 0.159 | ||
ICD, n % | 9 (1.9%) | 8 (2.8%) | 1 (0.5%) | 0.087 | ||
Single/dual chamber pacemaker, n % | 238 (50.5%) | 131 (45.3%) | 107 (58.8%) | 0.004 | ||
Pacing site | 0.006 | |||||
RV pacing, n % | 166 (35.2%) | 101 (34.9%) | 65 (35.7%) | |||
His-Pukenje system pacing, n % | 72 (15.3%) | 30 (22.9%) | 42 (39.3%) |
AVB, atrioventricular block; BMI, body mass index; OSAHS, obstructive sleep apnea-hypopnea syndrome; NYHA, New York Heart Association; Mild AVB, 1st-degree or Mobitz type I AVB; Advanced AVB, Mobitz type II or high-degree AVB or third-degree AVB; LBBB, left bundle branch block; ECG, electrocardiogram; RBBB, right bundle branch block; VT, ventricular tachycardia; TAPSE, tricuspid annular plane systolic excursion; LVEF, left ventricular ejection fraction; HFrEF, heart failure with reduced ejection fraction; NT-proBNP, N-terminal B-type natriuretic peptide; CK, creatine kinase; CIED, cardiac implantable electronic device; CRT(D), cardiac resynchronization therapy (defibrillator); ICD, implantable cardiac defibrillator; RV, right ventricle. The continuous parameters were displayed as mean (standard deviation) or median (25%, 75% interquartile).
As shown in Fig. 2, AVB etiology was identified in only 289 (61.4%) patients. The most commonly known etiology was NICM (n = 78, 16.6%), followed by complications associated with cardiac surgery (n = 63, 13.4%), IHD (n = 35, 7.4%), CHD (n = 32, 6.8%), and vagal-mediated AVB (n = 20, 4.3%). AVB was attributed to myocarditis, complications from ablation, LQTs/BrS, infiltrative cardiomyopathy, and CAVB; endocrine or hereditary causes were in relatively low proportion (overall 12.5%). We found no evidence of any confirmed medication-induced AVB cases in this sample. Notably, no attributable etiology was determined in 38.6% of the patients.
Etiological distributions of AVB in patients
We observed statistically significant differences in the proportions of etiology
distribution among different age and sex groups (all p
Clinical profiles of young AVB patients are presented in Table 1. In sum,
patients with unknown etiologies had fewer symptoms of syncope, dizziness, and
fatigue (all p
Previous studies have reported that Mobitz II, high-degree, and third-degree AVB routinely compromise the major pacing indication in AVB patients, and suggested that left-ventricle structure and function potentially affect a patient’s prognosis even after pacing therapy [1, 30, 31]. Therefore, we analyzed the etiologic distribution targeting AVB severity as well as left ventricle structural and functional change. Profiles of AVB severity and LV change across different etiologies are illustrated in Fig. 3. Although we found heterogeneity across groups, with regard to AVB severity and LV change, there were typical features of etiology distribution in different conditions. Specifically, NICM was the predominant etiology in those with LV structural or functional change with advanced AVB. On the other hand, vagal-mediated AVB accounted for the highest proportion of etiology in mild AVB with normal LV. Besides, AVB patients with unknown etiologies constitute a high proportion of those having advanced AVB with and without LV change (Fig. 3).
AVB severity and left ventricle structural or functional change in relation to different etiologies. (A) Etiology distribution in the young patients with advanced AVB and LV structural/functional change. (B) Etiology distribution in the young patients with advanced AVB but normal LV structure and function. (C) Etiology distribution in the young patients with mild AVB and LV structural/functional change. (D) Etiology distribution in the young patients with mild AVB and normal LV structure and function. Advanced AVB: Mobitz Type II AVB, high-degree AVB, or third-degree AVB. LV structural/functional change: abnormal left ventricular ejection fraction borderline/elevated left ventricular end diastolic diameter. AVB, atrioventricular block; LV, left ventricle; CHD, congenital heart disease; IHD, ischemic heart disease; NICM, non-ischemic cardiomyopathy; others comprise the etiologies with percentage lower than 1%, including AVB related to infiltrative cardiomyopathy, neuromuscular disease, long QT or Brugada syndrome, congenital AVB, endocrine or hereditary causes.
Considering the significant distribution of the unknown etiology group in the
above conditions, we further explored the clinical characteristics of 182 AVB
patients with unknown etiologies. We found significant differences in demographic
features across the four groups; the structural change-dominated phenotype and
mild phenotype were in younger and more likely male patients. There were no
statistically significant differences in comorbidities, except for a high
proportion of obstructive sleep apnea-hypopnea syndrome in the mild phenotype.
Patients with severe phenotypes accounted for 17.03% of the undetermined
etiology group, they tended to exhibit lower heart rates and a higher proportion
of third-degree AVB than did those with other phenotypes (Table 2). A total of
110 (out of the 182) patients finally received pacing therapy. Complete follow-up
was achieved in 98 of them, with 4 refusing to consent to follow-up and 8 losing
follow-up. We found no statistically significant differences in baseline features
between the total (n = 110) and just those with complete survival information
(Supplementary Table 2). Analysis of the aforementioned four
phenotypes revealed that 25 of the patients exhibited the severe phenotype, and
75 with the advanced AVB phenotype were pacemaker recipients. On the other hand,
only 8 and 2, respectively, of the patients in the mild and LV change-dominated
groups received pacing therapy (Supplementary Table 2). We recorded no
deaths at a median follow-up of 17.5 months, but 16 patients reported (at least
once) new-onset of HF symptoms. Among them, 2 were hospitalized because of the
symptom. In 64 (13 with susptected HFEs, 51 without suspected HFEs) of the 98
(65.3%) patients whose follow-up echocardiographic results were also aviliable,
we compared LVEDD and LVEF alteration in those with and without suspected HFEs.
There is significant increase in LVEDD (p = 0.0249) and reduction in
LVEF (p
Kaplan-Meier survival curves of event-free survival stratified by severe and non-severe clinical phenotypes among pacemaker recipients with unknown etiology. Patients with complete follow-up information were included for analysis. Heart failure events include new onset of heart failure-related symptoms and signs and unplanned hospitalization due to the symptoms. Log-rank test was applied for survival rate comparison.
Variables | Mild phenotype (n = 51) | AVB dominant (n = 94) | LV structural change dominant (n = 6) | Severe phenotype (n = 31) | p-value | ||
Age, yrs | 31.82 |
36.76 |
25.83 |
36.90 |
0.016 | ||
Male sex, n % | 34 (66.67%) | 44 (46.81%) | 5 (83.33%) | 16 (51.61%) | 0.060 | ||
BMI, kg/m |
24.14 |
23.16 |
22.60 |
24.99 |
0.161 | ||
Asymptomatic, n % | 17 (33.33%) | 8 (8.51%) | 1 (16.67%) | 3 (9.68%) | |||
Onset age, yrs | 30.90 |
32.54 |
24.67 |
32.68 |
0.480 | ||
Family history, n % | 4 (7.84%) | 6 (6.38%) | 0 (0.00%) | 2 (6.45%) | 0.905 | ||
Comorbidities | |||||||
Coronary artery disease, n % | 3 (5.88%) | 7 (7.45%) | 0 (0.00%) | 0 (0.00%) | 0.414 | ||
Valve disease, n % | 5 (9.80%) | 5 (5.32%) | 0 (0.00%) | 3 (9.68%) | 0.620 | ||
Pulmonary artery hypertension, n % | 3 (5.88%) | 9 (9.57%) | 2 (33.33%) | 5 (16.13%) | 0.130 | ||
Stroke, n % | 0 (0.00%) | 2 (2.13%) | 0 (0.00%) | 2 (6.45%) | 0.273 | ||
OSAHS, n % | 9 (17.65%) | 2 (2.13%) | 0 (0.00%) | 0 (0.00%) | |||
Diabetes, n % | 4 (7.84%) | 6 (6.38%) | 0 (0.00%) | 2 (6.45%) | 0.905 | ||
Myocarditis, n % | 0 (0.00%) | 1 (1.06%) | 0 (0.00%) | 1 (3.23%) | 0.588 | ||
Thyroid disease, n % | 2 (3.92%) | 5 (5.32%) | 0 (0.00%) | 0 (0.00%) | 0.566 | ||
Hypertension, n % | 8 (15.69%) | 13 (13.83%) | 0 (0.00%) | 8 (25.81%) | 0.295 | ||
Heart rate, bpm | 70.00 (62.50–75.00) | 51.00 (40.25–64.50) | 62.50 (61.25–78.75) | 43.00 (40.00–50.00) | |||
Persistent AVB, n % | 2 (3.92%) | 36 (38.30%) | 0 (0.00%) | 16 (51.61%) | |||
Other ECG features | |||||||
Atrial fibrillation/flutter, n % | 5 (9.80%) | 12 (12.77%) | 1 (16.67%) | 7 (22.58%) | 0.419 | ||
LBBB, n % | 0 (0.00%) | 9 (9.57%) | 1 (16.67%) | 2 (6.45%) | 0.114 | ||
RBBB, n % | 3 (5.88%) | 9 (9.57%) | 0 (0.00%) | 2 (6.45%) | 0.736 | ||
Non-sustained VT, n % | 3 (5.88%) | 5 (5.32%) | 1 (16.67%) | 3 (9.68%) | 0.624 | ||
NYHA class | 1.1 |
1.1 |
1.5 |
1.5 |
|||
I, n % | 46 (90.2%) | 87 (92.6%) | 4 (66.7%) | 21 (67.7%) | 0.011 | ||
II, n % | 4 (7.8%) | 5 (5.3%) | 1 (16.7%) | 6 (19.4%) | |||
III, n % | 1(2.0%) | 2 (2.1%) | 1 (16.7%) | 4 (12.9%) | |||
IV, n % | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |||
Left atrial diameter, mm | 32.37 |
34.19 |
39.17 |
39.90 |
|||
Left ventricular end diastolic diameter, mm | 46.49 |
47.04 |
60.33 |
57.52 |
|||
Left ventricular ejection fraction, % | 64.80 |
62.96 |
54.67 |
59.71 |
|||
Right ventricular diameter, mm | 23.14 |
22.93 |
22.67 |
24.61 |
0.295 | ||
Abnormal TAPSE, n % | 2 (3.92%) | 2 (2.13%) | 0 (0.00%) | 0 (0.00%) | 0.673 | ||
NT-proBNP, pg/mL | 29.00 (14.05–82.05) | 72.60 (33.12–429.52) | 90.00 (34.25–244.75) | 147.70 (85.45–471.50) | |||
CK, IU/L | 83.00 (56.00–110.50) | 71.50 (56.50–98.75) | 68.00 (60.50–80.75) | 83.00 (61.50–113.00) | 0.438 |
AVB, atrioventricular block; LV, left ventricle; BMI, body mass index; OSAHS,
obstructive sleep apnea-hypopnea syndrome; ECG, electrocardiogram; LBBB, left
bundle branch block; RBBB, right bundle branch block; VT, ventricular
tachycardia; TAPSE, tricuspid annular plane systolic excursion; NYHA, the New York Heart Association; NT-proBNP,
N-terminal B-type natriuretic peptide; CK, creatine kinase. The continuous
parameters were displayed as mean
Severe phenotype | Non-severe phenotype | ||
Median follow-up duration, months | 16.54 | 17.52 | |
Number, n | 22 | 76 | |
Events, n | 7 | 9 | |
Cox regression | |||
HR unadjusted | 3.31 | ref | |
95% CI | 1.20–9.12 | ||
p-value | 0.021 | ||
HR minimally adjusted |
3.38 | ref | |
95% CI | 1.20–9.51 | ||
p-value | 0.021 | ||
HR fully adjusted |
3.46 | ref | |
95% CI | 1.10–10.84 | ||
p-value | 0.033 | ||
Logistic regression | |||
OR unadjusted | 3.47 | ref | |
95% CI | 1.12–10.81 | ||
p-value | 0.032 | ||
OR minimally adjusted |
3.56 | ref | |
95% CI | 1.10–11.50 | ||
p-value | 0.034 | ||
OR fully adjusted |
4.56 | ref | |
95% CI | 1.11–18.38 | ||
p-value | 0.033 |
a. Adjusted for age and sex. b. Adjusted for age, sex, NYHA classes II-III, CAD, PH, valve, log (NT-proBNP), pacing type and LBBB. AVB, atrioventricular block; HR, hazard ratio; OR, odds ratio; CI, confidence interval; ref, represent that non-severe phenotype was set as a reference in the regression model.
In this study, we first comprehensively described the etiologic distribution and clinical features of AVB in a Chinese sample of patients under 50 years of age. Our results revealed various etiologies that cause AVB with distinct age- and sex-specific distributions, of which NICM and complications from cardiac surgery were the top known etiologies. Notably, the specific cause of AVB could not be determined in 38.6% of the patients, which indicates that there is still a large gap in etiologic diagnoses in this group. Next, we summarized distinct clinical features observed in AVB patients with unknown etiologies, targeting AVB severity and LV change. Results showed that patients with severe phenotype featuring advanced AVB and abnormal LV structure/function were associated with a significantly higher risk of HF symptoms, even after pacing therapy, than did their counterparts with less severe phenotypes.
The high AVB proportions in underdiagnosed patients observed in this study are consistent with findings from a previous larger registry from Denmark, which reported a higher proportion (50.3%) [9]. The discrepancy between studies might be due to differences in the study period and population. In the Denmark registry study, the authors analyzed etiology based on an earlier period (between 1996 and 2015), whereas our study was based on clinical data obtained between 2019 and 2022, a period when the guidelines about diagnostic tests of bradycardia, including imaging and laboratory tests, have markedly advanced. It should be noted that there is also difference in the study population. The Danish registry study mainly focused on etiologic distribution among pacemaker receivers, in which third-degree AVB dominate the study population. In comparision ,we analyzed the etiology in consecutive AVB patients both with and without pacemaker implantation, with advanced or third-degree AVB accounting for only 57.7% of the study population. Therefore, the seemingly low rate of syncope or amaurosis was observed in our study. But the analysis was restricted to the high-degree and third degree AVB subgroup (n = 272), these symptoms were still commonly seen in 30.5% patients as previously reported [9].
Analysis of AVB etiology revealed a specific difference between sexes. In sum, NICM, IHD, neuromuscular disease, and vagal-mediated AVB were the dominant AVB causes in men, whereas cardiac surgery, CHD, myocarditis, and immune disease were the main causes in women. A similar distribution pattern was also observed in sex distribution of the etiologies themselves, therefore, the patterns can provide clues for etiologic screening across different sex groups upon detection of AVB onset. Moreover, premature IHD should also be considered and checked at the time of AVB diagnosis in this group owing to the distinctly high proportion of IHD-mediated AVB in patients aged 36–50 years. Analysis of the relationship between etiology and AVB severity and LV structure/function revealed that AVB due to cardiac surgery accounts for a higher proportion in the advanced AVB without LV change phenotype. By contrast, as a leading cause of AVB in young patients, NICM is a progressive disease and a major cause of AVB, and tends to be accompanied by advanced AVB and LV change, which should raise concern. Previous studies have reported that NICM patients exhibit a high burden of various AVBs, which may also serve as the primary manifestation before onset of cardiac dysfunction [32, 33]. AVB patients with NICM exhibited significant changes in LV structure and function, with approximately 60% having advanced AVB. Importantly, the previously reported lower rate of NICM-related AVB in pacemaker receivers mainly included those with advanced AVB. Previous studies have also demonstrated that even first-degree AVB is not as benign as expected, and not only serves as an early marker but also as an indicator for poor prognosis [34]. Therefore, we recommend that NICM be considered as an etiology during diagnosis of AVB in young patients, and comprehensively evaluated using advanced laboratory or imaging tests.
AVB patients with unknown etiologies exhibited a low rate of abnormal LVEF, better NYHA class, and lower NT-proBNP levels than did their counterparts with known etiologies. A previous study reported that AVB patients younger than 50 with unknown etiologies also displayed a high risk of poor prognosis even under pacing therapy, indicating that AVB with unknown etiologies also might not be as benign as expected [10]. Results from the present study showed that although etiologies with pronounced phenotype and clear histories, such as surgery, CHD, IHD, or ablation-induced AVB, can be generally ruled out of the patients’ unknown etiologies, particular diseases such as hereditary AVB, infiltrative CM, NICM, and neuromuscular disease can be mixed in with undetermined etiologies. This can be restricted by either the preclinical stage of the disease or the lack of detailed testing approaches. After all, besides the ECG, echocardiography, and myocardial biomarker tests, the overall proportion of advanced special tests were low: molecular-genetic testing (1.6%), myocardial biopsy (0.5%), cardiovascular magnetic resonance (13.2%), positron emission/ single-photon emission computed tomography imaging (3.3%), or antibody test (11%). We also speculate that a lack of these particular tests might be responsible for misidentification of the proportion of corresponding etiologies, whereas the actual proportion of those systematic, progressive, rare but latent etiologies, might be higher than presented herein.
Even in the absence of clear etiologies in primary care, clinicians should also
consider identifying the potential malignant phenotype that might affect patient
prognosis. Based on the previously mentioned AVB severity and LV change, AVB
patients with unknown etiologies were divided into four types with distinctive
characteristics, of which 17% showed risk features such as advanced AVB,
increased LVEDD, and high NT-proBNP levels [35, 36] and were classified as the
severe phenotype. Among AVB patients with undetermined etiologies who received
pacemakers, those who presented with severe phenotype were associated with a
triple risk of developing HF symptoms and signs. In the same subgroup, those who
received traditional RV pacing (n = 11) exhibited a higher rate of suspected HFEs
than did those in the physiological pacing (1 CRT and 10 left bundle branch area
pacing) group (54.5% vs 9.1%). Although this clinical phenotype cannot
substitute for a definitive etiologic diagnosis for AVB, these observations are
of clinical importance as they will guide future characterization of the
patients’ risk even if the cause is obscure and the overall LVEF is normal (59.7
Considering that this was a retrospective study, although we predetermined the diagnostic work-up and data collection spectrum, and included those with complete information, the same well-defined testing series cannot be guaranteed during the real diagnosis phase. Diagnosis of some etiologies may also be restricted by the lack of a key diagnostic test, thereby resulting in a lower proportion of some rare diseases. Another limitation was the exclusion of 7% of patients due to a lack of medical records. However, we found no statistically significant differences in demographic features and comorbidities between enrolled and excluded cases. In addition, the suspected HFE was mainly based on signs and symptoms rather than on objective measurements during follow-up of pacemaker recipients with unknown AVB reasons due to the high proportion of missing echocardiographic results during follow-up. But in the 65.3% patients with both symptom/signs evaluation and echocardiographic results, the suspected HFEs were in parallel with LVEDD and LVEF alteration. And previous studies have shown agreement between the self-reported HF symptoms and objective medical evaluation [37]. Finally, the small number of events observed limited multivariate analysis, and there might be the possibility of overfitting after adjusting for multiple confounders. Considering these limitations, there should be caution when interpreting these findings: this study was for description and hypothesis generation rather than seen as definitive claims. Further long-term follow-up for hard clinical endpoints and results from prospective studies are required.
The etiologies of AVB in young inpatients are diverse but still underdiagnosed. The etiology distribution has age- and gender-specific patterns. As a progressive condition, NICM is a leading cause of AVB characterized by predominate LV structural or functional change, which warrants attention upon clinical diagnosis of AVB. And among patients with unknown AVB etiologies, those with severe phenotype with a change of LV structure and advanced AVB were at a relatively higher risk of suspected HF symptom onset despite pacing therapy, and deserved further investigation. These findings provide new insights into the clinical characteristics and complexity of AVB in young AVB patients and emphasize the need for etiology diagnosis. Future studies are needed to raise the etiologic diagnosis rate, investigate the contribution of etiology to prognosis, and explore the appropriate pacing strategies for young AVB patients.
AVB, atrioventricular block; BMI, body mass index; OSAHS, obstructive sleep apnea-hypopnea syndrome; LVEF, left ventricular ejection fraction; LVEDD, left ventricle diastolic diameter; NICM, non-ischemic cardiomyopathy; HF, heart failure; CIED, cardiac implantable electronic device.
The datasets supporting this work are available from the corresponding author on reasonable request.
KC and YD designed the study. ZC and YJ performed the research, collected information, analyzed data and draft the manuscript. NX provided help and advice on the echocardiographic data analysis and interpretation. YG and SW assisted in follow-up of participants. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.
The study was approved by the Ethics Committee of Fuwai Hospital (IRB Approval NO. 2022-1788), and informed consent obtained from all participants.
Not applicable.
This work was supported by the National Natural Science Foundation of China (Grant Number 81870260), High-level Hospital construction project of Fuwai Hospital (Grant Number 2022-GSP-GG-31), Fundamental Research Funds for the Central Universities (Grant Number 3332021024) and CAMS Innovation Fund for Medical Sciences (CIFMS) (Grant Number 2022-I2M-C&T-B-049).
The authors declare no conflict of interest.
Publisher’s Note: IMR Press stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.